Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50line pembrolizumab.
Alex Friedlaender,Giulio Metro,Diego Signorelli,Alessio Gili, Panagiota Economopoulou,Fausto Roila,Giuseppe Banna,Alessandro De Toma,Andrea Camerini,Athina Christopoulou,Giuseppe Lo Russo,Marco Banini,Domenico Galetta,Beatriz Jimenez,Ana Collazo-Lorduy,Antonio Calles,Panagiotis Baxevanos,Helena Linardou,Paris Kosmidis,Giannis Mountzios,Marina C. Garassino,Alfredo Addeo Acta Oncologica（2020）
AI 理解论文
溯源树
样例
